Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Bio-Techne (TECH) over the last 17 years, with Q4 2025 value amounting to $5.9 million.

  • Bio-Techne's Capital Expenditures fell 1319.45% to $5.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $26.3 million, marking a year-over-year decrease of 4783.79%. This contributed to the annual value of $31.0 million for FY2025, which is 5068.79% down from last year.
  • Per Bio-Techne's latest filing, its Capital Expenditures stood at $5.9 million for Q4 2025, which was down 1319.45% from $5.4 million recorded in Q3 2025.
  • Bio-Techne's Capital Expenditures' 5-year high stood at $18.0 million during Q2 2024, with a 5-year trough of $4.9 million in Q2 2025.
  • Over the past 5 years, Bio-Techne's median Capital Expenditures value was $10.4 million (recorded in 2021), while the average stood at $10.5 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 14331.31% in 2023, then tumbled by 7280.31% in 2025.
  • Over the past 5 years, Bio-Techne's Capital Expenditures (Quarter) stood at $10.2 million in 2021, then tumbled by 39.92% to $6.1 million in 2022, then skyrocketed by 143.31% to $14.9 million in 2023, then tumbled by 54.11% to $6.8 million in 2024, then decreased by 13.19% to $5.9 million in 2025.
  • Its last three reported values are $5.9 million in Q4 2025, $5.4 million for Q3 2025, and $4.9 million during Q2 2025.